The pharmaceutical industry depends heavily on research infrastructure, scientific collaboration and access to specialist talent. GSK's latest Cambridge investment highlights how these factors are shaping modern pharmaceutical R&D.
GSK plans to establish a 300,000 sq ft R&D centre at Cambridge Biomedical Campus, with more than 1,000 scientists expected to work there. The company has announced a Β£400 million investment in UK life sciences over three years.
Why Cambridge?
Cambridge has developed a strong ecosystem connecting:
Universities
Hospitals
Biomedical research
Biotechnology companies
Pharmaceutical organisations
Clinical research
GSK says its new location will help researchers work within this ecosystem and strengthen translational researchβthe process of connecting scientific discoveries with clinical applications.
Research Focus
The centre will support GSK's focus areas including oncology, respiratory diseases, hepatology, vaccines and HIV.
The move also involves changes to GSK's UK research network, including vacating the Stevenage R&D site by 2029 and upgrading facilities in Ware.
For developers, researchers, students and technology professionals interested in healthcare technology, biotechnology, pharmaceutical R&D and scientific innovation, the Cambridge project provides an interesting example of how research ecosystems can influence innovation.
π Read more:
https://thecampusreview.com/news/gsk-cambridge-research-campus/
Top comments (0)